Clinical trials: Hypertrophy, Left Ventricular
Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy
Long Term Effects of Enalapril and Losartan on Genetic Heart Disease
The human heart is divided into four chambers. One of the four chambers, the left ventricle, is the chamber mainly responsible for pumping blood out of the heart into circulation.
- Conditions
- Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy, Myocardial Ischemia
- Trial name
- NCT00001534
- Testing
- Losartan
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
End-stage Renal Disease, Left Ventricular Hypertrophy
Impact of In-centre Nocturnal Hemodialysis on Ventricular Remodeling and Function in End-stage Renal Disease
Background: Recent data indicate that home nocturnal hemodialysis (8 hours of hemodialysis at home for 5-6 nights per week) may have substantial cardiovascular benefits, including regression of left ventricular (LV) hypertrophy…
- Trial name
- NCT00718848
- Testing
- Incentre nocturnal hemodialysis, Remaining on conventional hemodialysis
- Where
- 2 sites in Canada
- Volunteers
- 67 people
- Sponsor
- Unity Health Toronto
End Stage Renal Disease / Hemodialysis
Mineralocorticoid Receptor Antagonists in End Stage Renal Disease
End stage renal disease (ESRD) patients exhibit an extraordinarily high annual mortality. Cardiovascular (CV) causes account for almost half of all-cause mortality.
- Trial name
- MiREnDa (NCT01691053)
- Testing
- Spironolactone
- Where
- 3 sites in Germany
- Volunteers
- 118 people
- Sponsor
- Wuerzburg University Hospital
Dilated Cardiomyopathy, Arrhythmogenic Cardiomyopathy
Image-Based Prediction of Ventricular Tachycardia Events in Non-ischemic Cardiomyopathy
Risk stratification for sudden cardiac death (SCD) in patients with non-ischemic cardiomyopathy (NICM) remains suboptimal. Although current guidelines rely on severe left ventricular systolic dysfunction (left ventricular…
- Conditions
- Dilated Cardiomyopathy, Arrhythmogenic Cardiomyopathy, Ventricular Arrhythmia, Hypertrophic Cardiomyopathies
- Trial name
- IMPROVE-NICM (NCT06730464)
- Where
- 4 sites in Italy, Portugal and 1 more
- Volunteers
- 500 people
- Sponsor
- Centro Medico Teknon
Left Ventricular Hypertrophy, Hypertension
Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG
Assess the efficacy of fimasartan on left ventricular hypertrophy in hypertensive patients
- Trial name
- NCT03219632
- Testing
- Fimasartan
- Volunteers
- 72 people
- Sponsor
- Seoul National University Bundang Hospital
End Stage Renal Disease, Left Ventricular Hypertrophy
Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study
Kidney patients on dialysis commonly die because of heart disease. One of the biggest problems in their hearts is that the muscle wall of the heart thickens. This makes it less efficient.
- Trial name
- Altered (NCT01951404)
- Testing
- Allopurinol
- Where
- 3 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- University of Dundee
Hypertensive Left Ventricular Hypertrophy
Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy
The primary objective of this study is to determine which treatment will be more effective to reduce left ventricular mass in hypertensive patients with left ventricular hypertrophy comparing aliskiren and eplerenone.
- Trial name
- EARTH (NCT01893788)
- Testing
- Aliskiren, Eplerenone
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Nagoya University
Hypertension
Predictive Factors of Systolic Dysfunction in Non-complicated Hypertensive Patients
Hypertension is a major cardiovascular risk factor. Heart failure is one of its main complications but the factors that influence its development are still insufficiently known.
- Trial name
- GLOBAL-HTN (NCT02841696)
- Testing
- Cardiac echography
- Where
- France
- Volunteers
- 183 people
- Sponsor
- University Hospital, Bordeaux
Cardiovascular Diseases, Cardiovascular Morbidity
Assessment and Digital-health Based Intervention on Subclinical Organ Damage and Cardiovascular Risk in Chinese
To comprehensively evaluate subclinical organ damage of Chinese adults and its association with future cardiovascular disease and events.
- Conditions
- Cardiovascular Diseases, Cardiovascular Morbidity, Subclinical Organ Damage, Digital Health
- Trial name
- NCT05435898
- Where
- China
- Volunteers
- 4,000 people
- Sponsor
- Shanghai 10th People's Hospital
Heart Failure
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure.
- Trial name
- 8282-Reduced (NCT06979375)
- Testing
- CDR132L
- Where
- 92 sites in Australia, Czechia and 8 more
- Volunteers
- 200 people
- Sponsor
- Novo Nordisk A/S
Left Ventricular Hypertrophy
Protective Monocytes and Macrophages to Limit Decompensation and Heart Damaging
The working hypothesis is that cardiac macrophages specific for the compensated cardiac hypertrophic phase limit the progression toward the decompensated state of heart failure by promoting an inflammatory environment favouring…
- Trial name
- PROMOMA (NCT04022330)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
This study aims to evaluate whether, under a treatment strategy primarily guided by left ventricular ejection fraction (LVEF), dose up-titration in adult patients with symptomatic obstructive hypertrophic cardiomyopathy who have…
- Trial name
- NCT07807384
- Testing
- Mavacamten
- Volunteers
- 115 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Left Ventricular Ejection Fraction, Cardiac Magnetic Resonance Imaging
Evaluation of Left Ventricular Ejection Fraction Using an Accelerated Cardiac Cine-MRI Sequence With Deep Learning-based Image Reconstructions
Left ventricular hypertrophy (LVH) is a common condition that may result from hypertension, hypertrophic cardiomyopathy, aortic valve stenosis, or certain metabolic disorders.
- Conditions
- Left Ventricular Ejection Fraction, Cardiac Magnetic Resonance Imaging, Deep Learning, Image Reconstruction
- Trial name
- HVGLD (NCT07061821)
- Testing
- accelerated cardiac cine-MRI sequence
- Where
- France
- Volunteers
- 61 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Cardiomyopathies, Dilated Cardiomyopathy
Pediatric Cardiomyopathy Mutation Analysis
The goal of this protocol is to obtain information from individuals with cardiomyopathy and from their families in order to elucidate the molecular genetics of this disorder.
- Conditions
- Cardiomyopathies, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy
- Trial name
- NCT02432092
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Indiana University
Heart Failure
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure.
- Trial name
- 8212-Preserved (NCT06979362)
- Testing
- CDR132L
- Where
- 118 sites in United States, Canada and 7 more
- Volunteers
- 200 people
- Sponsor
- Novo Nordisk A/S
Hypertrophy, Left Ventricular, Hypertension
Effect of a Targeted Notification and Clinical Support Pathway on Individuals With Left Ventricular Hypertrophy
The electronic health record contains vast amounts of cardiovascular data, including potential clues that an individual may have unrecognized cardiac conditions.
- Conditions
- Hypertrophy, Left Ventricular, Hypertension, Cardiomyopathies
- Trial name
- NOTIFY-LVH (NCT05713916)
- Testing
- Intervention: Population Health Coordinator
- Where
- United States
- Volunteers
- 648 people
- Sponsor
- Massachusetts General Hospital
Heart Failure
The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients
This is a phase IV, prospective, randomized, double-blind, double-dummy, parallel-group study. The study assessed the effects of 6 weeks of stable sacubitril/valsartan therapy, as compared with valsartan therapy, on the…
- Trial name
- TurkuPET (NCT03300427)
- Testing
- sacubitril/valsatran, valsartan
- Where
- Finland
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Diastolic Dysfunction, Left Ventricular Hypertrophy
Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy
This is a clinical, randomised, double-blinded study in which patients eligible for aortic valve replacement are enrolled. Patients receive infusion of either levosimendan or placebo 4 hours prior to surgery and until the end of…
- Trial name
- NCT01188369
- Testing
- levosimendan
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- University of Aarhus
Left Ventricular Hypertrophy
Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot Study
This is a prospective, open label, single-center study, in kidney transplant recipients with stable renal function for 12 and 120 months after transplantation, that are in use use of calcineurin inhibitors, azathioprine, and…
- Trial name
- NCT02493465
- Testing
- Everolimus
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Instituto de Urologia e Nefrologia
Cardiovascular Diseases, Left Ventricular Hypertrophy
Empagliflozin and Cardiac Remodelling in People Without Diabetes
The purpose of this study is to evaluate the effects of empagliflozin on cardiac structure, function and circulating biomarkers in patients with cardiovascular risk factors, but without diabetes.
- Trial name
- EMPA-HEART 2 (NCT04461041)
- Testing
- Empagliflozin
- Where
- 4 sites in Canada, Taiwan
- Volunteers
- 169 people
- Sponsor
- Unity Health Toronto